SCIENMAG: Medicine & Health

AUGUST 28, 2023

military veterans with coronary artery disease, suboptimal lipid-lowering therapy was prevalent in the clinical setting. Optimization of statin therapy was projected to produce clinically relevant reductions in the risks of death and cardiovascular events. About The Study: In this study of 111,000 U.S.

Therapies 84

Therapies Disease 84

Covalent Modifiers

AUGUST 14, 2024

Rullo Molecular Therapy 2024 DOI: [link] Proximity-induction of cell-cell interactions via small molecules represents an emerging field in basic and translational sciences. We determined that covalent linkage enforced early T cell activation events in a manner that was dependent upon each SARs biology and signaling threshold.

Small Molecule 182

Small Molecule Engineering Science Therapies 182

ASPET

JUNE 30, 2023

Myeloproliferative Neoplasms (MPNs) are hematological malignancies that result from acquired driver mutations in hematopoietic stem cells (HSCs), causing overproduction of blood cells and an increased risk of thrombo-hemorrhagic events. The most common MPN driver mutation affects the JAK2 gene ( JAK2 V617F ).

Therapies 100

Therapies Treatment Drugs 100

ASPET

JUNE 27, 2024

Estrogen receptor (ER)-negative breast cancers are known to be aggressive and unresponsive to anti-estrogen therapy, and triple negative breast cancers are associated with poor prognosis and metastasis. Thus, new targeted therapies are needed.

Therapies 100

Therapies Protein Expression 100

Drug Patent Watch

DECEMBER 17, 2024

Contract Development and Manufacturing Organizations (CDMOs) are at the forefront of this shift, playing a crucial role in bringing innovative therapies to market. Flexible CDMOs can quickly pivot to meet these changing needs, ensuring uninterrupted supply chains and faster time-to-market for critical therapies.

Pharmaceuticals 90

Pharmaceuticals Therapies Production Pharmaceutical Companies 90

Advarra

NOVEMBER 14, 2024

The DSMB’s primary responsibilities include : Monitoring patient safety: Ensuring participants are not exposed to undue risk and adverse events are promptly identified and addressed. For example, consider a global Phase III, double-blind study, in a novel new therapy.

Clinical Trials 97

Clinical Trials Trials International Clinical Research 97

Drug Target Review

DECEMBER 23, 2024

While these therapies hold great promise for improving cancer treatment outcomes, their development presents significant challenges, especially in achieving the optimal balance between efficacy and safety. Most patients are given combination therapies to enhance efficacy, explains Wang.

Research 52

Research Treatment Therapies Drug Development 52

Drug Discovery Today

FEBRUARY 4, 2022

• Face-to-face event, taking place in London, UK, 26-27th April, will feature two dedicated tracks: ‘Scientific’, focused on seven core therapy areas and ‘Life Sciences Business’ Programme features keynote from George Freeman MP, with an update on the UK Government Life Sciences VisionRegistration for BioTrinity 2022 now available online

Science 113

Science Government Therapies 113

Elrig

MARCH 25, 2025

Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this years event focussed on drugging the undruggable.

RNA 59

RNA Bioinformatics Science Pharmacokinetics 59

Covalent Modifiers

JUNE 24, 2024

Rullo, Molecular Therapy: Oncology , 2024 , 200842, [link] Proximity-induction of cell-cell interactions via small molecules represents an emerging field in basic and translational sciences. Nickolas J. Serniuck, Eden Kapcan, Duane Moogk, Allyson E. Moore, Benjamin P.M. Lake, Galina Denisova, Joanne A. Hammill, Jonathan L. Bramson, Anthony F.

Small Molecule 130

Small Molecule Engineering Science Therapies 130

DrugBank

JANUARY 29, 2025

Gene Therapy Gene therapy operates on the principle of modulating the DNA blueprint of cells to induce a therapeutic response. Gene therapy trials explore using lentiviral vectors to deliver a functional copy of the HBB gene to hematopoietic stem cells, the progenitors of all blood cells.

Therapies 52

Therapies DNA RNA Disease 52

ASPET

AUGUST 2, 2024

Based on previous studies, we hypothesized that vascular senescence increases the risk of bleeding during warfarin therapy. The vascular senescence group tended to experience more bleeding or thromboembolic/ischemic events during one year of follow-up, while there was no statistical difference.

Therapies 100

Therapies Hospitals International 100

Broad Institute

NOVEMBER 25, 2024

The L2C Accelerator is focused on vastly shortening the time to develop therapies for rare disease patients by grouping together hundreds (or even thousands) of rare genetic mutations in parallel and identifying many candidate therapeutic targets (i.e. L2C2023 to view the full recording of the event and learn more about our research.

Clinical Trials 52

Clinical Trials Disease Trials Therapies 52

Vial

DECEMBER 8, 2023

With technological innovation and scientific research propelling the development of new therapies, anticipation for the future is high. As we look forward to 2024, several groundbreaking therapies are poised to radically change the landscape of ophthalmology, providing hope and improved treatment options for patients with ocular conditions.

Therapies 52

Therapies Clinical Trials Trials Treatment 52

Drug Target Review

AUGUST 6, 2024

Cardiovascular diseases : Atherosclerosis : ADCs could be engineered to target and deliver drugs to atherosclerotic plaques, potentially stabilising them and preventing cardiovascular events. Liver Fibrosis : Targeted therapies using ADCs could help reduce liver fibrosis and prevent the progression to cirrhosis.

Therapies 119

Therapies Pharmaceutical Companies Disease Treatment 119

Drug Channels

APRIL 4, 2022

Hybrid Event May 17-19, 2022 | Boston, MA www.informaconnect.com/rare. Come together with experts from across the rare disease community, in-person or virtually, to unite in areas of unmet medical need and create life-transforming therapies and breakthroughs. Rare Disease Innovation & Partnering Summit.

Disease 98

Disease Therapies FDA Trials 98

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Advarra

MARCH 20, 2023

The Food and Drug Administration (FDA) recently released new guidance regarding cellular and gene therapy products, one of which may significantly impact early-phase clinical trials of such products. This article explores the implications of this guidance, including new approaches for studies focused on cellular or gene therapies.

Therapies 52

Therapies FDA Trials Clinical Trials 52

Drug Channels

NOVEMBER 4, 2022

He suggests that lessons learned from the COVID-19 pandemic can inform both innovation in AMR therapies and our understanding of AMR. This virtual event is presented by OptimizeRx in collaboration with Melina Therapeutics. Read on for Matt’s insights.

Therapies 98

Therapies Marketing Drugs 98

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies 52

Therapies Virus DNA Compliance 52

Drug Target Review

JANUARY 2, 2024

Through a series of experiments, they successfully developed a personalised stem cell therapy using a data-driven, single-cell technique based on swift subcellular proteomic imaging. Our recent work proposes the use of an intracellular toolkit to map organelle bio-geography in stem cells that could lead to more precise therapies.”

RNA 128

RNA Immune Response Therapies Disease 128

The Pharma Data

JUNE 1, 2022

The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with hemophilia A, a rare and life-threatening bleeding disorder, based on data from the pivotal XTEND-1 P hase 3 stud y.

Therapies 52

Therapies FDA Science Treatment 52

Alta Sciences

JANUARY 17, 2025

WebinarPreclinical Studies of Gene Therapy Products: Latest Trends lperez Fri, 01/17/2025 - 22:48 Image Website_webinar_Preclinical Studies Gene Therapy_v2.jpg jpg Tags Preclinical Research URL [link] Event End Date Thu, 03/06/2025 - 12:00 Event Start Date Thu, 03/06/2025 - 12:00 Weight 1

Production 40

Production Therapies Research 40

Drug Channels

JULY 11, 2022

Delivered as a Hybrid Event. This important event convenes key stakeholders including manufacturers, specialty pharmacies, hub providers and more for unrivaled collaboration to leverage innovation and optimize access. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Compliance 98

Elrig

MAY 18, 2023

The most important drug discovery event of the year? 18-19 October 2023 The most important drug discovery event of the year? It’s with great excitement that we announce the return of ELRIG’s FREE TO ATTEND Drug Discovery 2023 (DD 2023); Europe’s leading event for the drug discovery community! Save the date! Save the date!

Drugs 40

Drugs Science Research Therapies 40

Drug Target Review

MARCH 17, 2025

However, a deeper understanding of brain function particularly the role of synaptic plasticity is now opening the door to innovative therapies. Event-driven pharmacology Donello highlights the growing recognition of synaptic plasticity’s crucial role in the biology of depression.

Treatment 52

Treatment Licensing Licensing Science 52

Alta Sciences

JANUARY 11, 2024

It is estimated that there are over 6,000 monogenic diseases, affecting over 350 million people worldwide; for these diseases, cell and gene therapy may provide hope for a cure. However, there are significant challenges associated with the successful development of these complex, leading-edge therapies. what is the altascientist?

Therapies 52

Therapies Immune Response Disease Virus 52

ASPET

JUNE 7, 2024

Acute Kidney Injury (AKI) is characterized by an abrupt decline in kidney function and has been associated with excess risks of death, kidney disease progression, and cardiovascular events. Significance Statement No approved pharmacological therapies currently exist for acute kidney injury.

Small Molecule 100

Small Molecule Therapies Disease 100

PPD

AUGUST 7, 2024

Clinical trials are the backbone of medical research, enabling the development of new treatments and therapies that can improve patient outcomes. Adverse Event Reporting and Safety Monitoring: During a clinical trial, participants may experience adverse events that may be related or unrelated to the study drug.

Clinical Trials 97

Clinical Trials Trials Compliance Clinical Research 97

Drug Target Review

OCTOBER 9, 2023

The potential of stem cell therapies is rooted in the pluripotency of these early embryonic stem cells. Dr Laura Kerosuo explains that their discoveries cast fresh illumination on the sequence of events in early embryonic development. This study was published in Nature Communications.

Therapies 110

Therapies Doctors Disease Research 110

Chemical Biology and Drug Design

MAY 11, 2023

Neuronal degeneration may arise due to a variety of pathological events, like inflammatory responses, neurotransmitter dysregulation, oxidative damage, mitochondrial malfunction, apoptosis, and genetic factors. Crocin, a naturally occurring carotenoid molecule, was found to have neuroprotective potential in the therapy of this disorder.

Disease 100

Disease Research Clinical Trials Treatment 100

ASPET

NOVEMBER 30, 2023

In this study, we evaluated the long-term efficacy of novel synthetic neurosteroids in preventing the development of chronic epilepsy and hyperexcitable ictal events in a rat OP model of SE. Similarly, the neurosteroid analog VX significantly attenuated SRS, discharges, HFOs, and ictal events.

Disease 100

Disease Therapies Treatment 100

Alta Sciences

OCTOBER 29, 2024

PBSS - San Francisco Bay—Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products iianiro Tue, 10/29/2024 - 20:55 Image foster_city_sunset.jpg Synopsis Foster City, CA URL [link] Event End Date Tue, 11/05/2024 - 12:00 Event Start Date Fri, 11/15/2024 - 12:00 Weight 1

Production 40

Production Therapies 40

The Pharma Data

MAY 27, 2022

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah ® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

FDA Approval 52

FDA Approval Therapies FDA Treatment 52

Drug Target Review

SEPTEMBER 25, 2024

Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades. The reactivation of oncogenic signalling upstream or downstream of the driving oncogene is a well-studied source of resistance to targeted cancer therapies.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Chemical Biology and Drug Design

FEBRUARY 13, 2024

Some researchers proposed that the symptoms involved in AD (loss of memory, cognitive impairment, and amnesia) are the main event linked to the cholinergic neurotransmitter (acetylcholine). Of the multiple hypotheses for AD, the cholinergic and amyloid-β (Aβ) hypothesis are the main targeting hypothesis for AD.

Disease 100

Disease Treatment Therapies Research 100